Last reviewed · How we verify
Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
This study is a prospective, observational, real-world investigation. This study will evaluate the efficacy and safety of tislelizumab monotherapy before surgery in patients with mismatch repair deficient or microsatellite instability high (dMMR/MSI-H) locally advanced colorectal cancer. All patients will receive three cycles of tislelizumab neoadjuvant therapy followed by curative surgery. Postoperatively, based on surgical pathology, patients will receive adjuvant therapy with a regimen selected by the investigator or adopt a watch-and-wait strategy. The investigators will conduct a 5-year prospective follow-up. The investigators plan to enroll approximately 30 subjects.
Details
| Lead sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
|---|---|
| Status | RECRUITING |
| Enrolment | 30 |
| Start date | Sun Feb 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Colo-rectal Cancer (dMMR/MSI-H CRC)
Countries
China